Atlas Trials

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Clinical trial NCT02254239 · TERMINATED

Trial details

NCT number
NCT02254239
Sponsor
Mayo Clinic
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Start date
2016-02-04
Primary completion
2018-12-12
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.